Clinical trial
Single-center, Prospective, Controlled Study of the Safety and Efficacy of Aspirin and Clopidogrel in Ischemic Cardiovascular and Cerebrovascular Patients Complications With CAA
NCT04654026 is registered in ClinicalTrials.gov with Shenzhen Second People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-center, Prospective, Controlled Study of the Safety and Efficacy of Aspirin and Clopidogrel in Ischemic Cardiovascular and Cerebrovascular Patients Complications With CAA
- Lead sponsor
- Shenzhen Second People's Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- February 20, 2021
- Completion date
- October 30, 2023
- Enrollment
- 43 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.